about
Drotrecogin alfa (recombinant human activated protein C) in severe acute pancreatitisQuality of life assessment in patients with chronic pancreatitis receiving antioxidant therapyInsulin protects pancreatic acinar cells from cytosolic calcium overload and inhibition of plasma membrane calcium pump.Radiofrequency ablation of liver tumours: systematic review.Randomised, double blind, placebo controlled trial of intravenous antioxidant (n-acetylcysteine, selenium, vitamin C) therapy in severe acute pancreatitis.The Plasma Membrane Calcium Pump in Pancreatic Cancer Cells Exhibiting the Warburg Effect Relies on Glycolytic ATP.Systematic appraisal of the role of metallic endobiliary stents in the treatment of benign bile duct stricture.Current status of laparoscopic biliary bypass in the management of non-resectable peri-ampullary cancer.Systematic appraisal of the management of the major vascular complications of pancreatitis.Contemporary management of infected necrosis complicating severe acute pancreatitisEvaluation of the Manchester classification system for chronic pancreatitis.Pro/con debate: antifungal prophylaxis is important to prevent fungal infection in patients with acute necrotizing pancreatitis receiving broad-spectrum antibiotics.Role of tumor necrosis factor-alpha in acute pancreatitis: from biological basis to clinical evidence.Current status of tumor M2 pyruvate kinase (tumor M2-PK) as a biomarker of gastrointestinal malignancy.Cytokine profiles in patients receiving antioxidant therapy within the ANTICIPATE trialUnderstanding the colonic complications of pancreatitis.Epidermal growth factor receptor in pancreatic cancer.Variance in elective surgery for chronic pancreatitis.Glycolytic ATP fuels the plasma membrane calcium pump critical for pancreatic cancer cell survival.Reappraisal of xenobiotic-induced, oxidative stress-mediated cellular injury in chronic pancreatitis: a systematic review.Experimental and clinical evidence for modification of hepatic ischaemia-reperfusion injury by N-acetylcysteine during major liver surgery.Recombinant human activated protein C as a disease modifier in severe acute pancreatitis: systematic review of current evidence.Determinant-based classification of acute pancreatitis severity: an international multidisciplinary consultation.The liver-first approach to the management of colorectal cancer with synchronous hepatic metastases: a systematic review.Mesh fixation at laparoscopic inguinal hernia repair: a meta-analysis comparing tissue glue and tack fixation.Management of colorectal cancer presenting with synchronous liver metastases.Minimally invasive and endoscopic versus open necrosectomy for necrotising pancreatitis: a pooled analysis of individual data for 1980 patients.Antibiotic use in acute pancreatitis: Global overview of compliance with international guidelines.Colorectal cancer with Synchronous liver-limited Metastases: the protocol of an Inception Cohort study (CoSMIC).Glucose metabolic phenotype of pancreatic cancer.Superior mesenteric artery (SMA) resection during pancreatectomy for malignant disease of the pancreas: a systematic review.Long-term outcome of patients with chronic pancreatitis treated with micronutrient antioxidant therapy.Efficacy and safety of pharmacological venous thromboembolism prophylaxis following liver resection: a systematic review and meta-analysis.Antibiotic use in acute pancreatitis: An audit of current practice in a tertiary centre.Patterns of progression, treatment of progressive disease and post-progression survival in the New EPOC study.Development and validation of an experimental model for the assessment of radiofrequency ablation of pancreatic parenchyma.Poly(adenylic acid) complementary DNA real-time polymerase chain reaction in pancreatic ductal juice in patients undergoing pancreaticoduodenectomy.Etanercept attenuates the development of cerulein-induced acute pancreatitis in mice: a comparison with TNF-alpha genetic deletion.Twenty-four hour infusion of human recombinant activated protein C (Xigris) early in severe acute pancreatitis: The XIG-AP 1 trial.Insulin protects pancreatic acinar cells from palmitoleic acid-induced cellular injury.
P50
Q24810923-D7B024C5-CD1D-458F-B5D9-56EAFD0E61C2Q34084966-A19320EA-5B70-499E-9C3B-69CD451CA6F2Q35693971-7702B740-917F-4C7B-B30F-208AFCE825D3Q35874711-B562543B-0FFA-4784-8944-E4961143390BQ36023455-5EA3A196-DB5A-4CC1-AAE7-1167BA092B86Q36139808-47532184-78AE-43C2-AAE4-C5667DB42E43Q36171718-C96FCA4C-AE07-464D-A309-2159D11BE721Q36175808-32BA2EF9-95A9-409E-B098-9D8F3F58A647Q36232478-8B956ED3-EB47-40C0-8D86-6E0F1E80C5EAQ36342719-2765C78E-29FB-4EA2-A58A-E228E7034435Q36532694-01A1317B-8ABC-40C0-BF56-70039997CA88Q36588446-9A40507C-4F2C-4567-B468-B70A0031A5F7Q36832083-DD3BA79F-3CC8-43EF-AF79-0A0258FFC418Q36865592-4C91DA3E-C3DA-40FA-A5CF-61BBAA7769EAQ36987850-F1AADD53-08EB-4148-8F26-80EC894BDF59Q37125631-0C22DDEE-8E97-4A33-A76E-1E38179BC1C1Q37132640-F40C5131-E19F-434D-8B3A-6BFDFF12B351Q37364385-E21B41C4-4277-4F40-B08D-125BAA33AF79Q37388840-96E0424E-B6BD-402B-8D83-F31038F4796BQ37654509-966D75F2-7707-4CAC-950A-309F4B43E684Q37829472-ADE709B1-7598-40C3-96E7-3EBBF29CD21FQ38001179-3F4A4C2C-9104-4D61-ABE8-359FD881D961Q38021899-03ABF220-7455-4205-9CCE-D879F6C8919BQ38110195-CF3154DF-8FC0-4E1F-9C81-6ACA16D4761CQ38207505-27883CB3-75CE-452F-8E08-9628AF1A2E8EQ38217004-63BCE6DF-7E3C-4E8D-BE55-01D704E303ECQ38642468-9FECD0C6-8A03-47BB-B33A-F36BCEBF95A8Q38709501-544334DB-7AE0-4722-907F-A0577379705BQ38732104-5DBDAE58-A0E8-429D-9915-D4B4EA83E747Q38791962-12ABD558-D22B-4391-AE85-F95A28E10FC8Q38836360-584A5F60-A74D-41FC-BBA3-8096E783A7A4Q38851732-B01F0507-5D79-4E30-AAE9-0BD4FC1D1E85Q38978304-EC2BBEE2-D89C-4DA6-BA56-B364A449C0F2Q39404999-6088AABF-E1B4-48DB-8661-23D222B0AF55Q39585475-00B746AA-897E-46FD-854C-0E6C8860E3D5Q39711381-AC7E8AE9-C28C-451A-B384-186CA002A33FQ39925799-7233F977-A6A1-40A8-BABF-813CE1FD4FD6Q40222756-9C2637CB-863F-4D49-812A-DBB664839399Q40345102-B82A68E4-F805-48C2-9B03-30E5F03C0484Q41985473-A5EACFDB-EB1C-4857-8FD7-1B46E5B07EF6
P50
description
researcher (ORCID 0000-0001-8004-0560)
@en
wetenschapper
@nl
name
Ajith K Siriwardena
@en
Ajith K Siriwardena
@nl
type
label
Ajith K Siriwardena
@en
Ajith K Siriwardena
@nl
prefLabel
Ajith K Siriwardena
@en
Ajith K Siriwardena
@nl
P31
P496
0000-0001-8004-0560